Unknown

Dataset Information

0

Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.


ABSTRACT: The direct oral anticoagulants (DOACs) are used for stroke prevention in atrial fibrillation (SPAF) and the prevention and treatment of venous thromboembolic disease (VTE). Although DOAC-associated bleeding events are less frequent as compared to vitamin K antagonists, there is significant concern surrounding physicians' ability to evaluate and manage DOAC-associated bleeding when it does occur. Idarucizumab is a specific reversal agent for dabigatran and is the agent of choice for dabigatran reversal in the setting of major bleeding or urgent surgery/procedures. There are no commercially available specific reversal agents for the direct Xa inhibitors. Although they have not been rigorously studied in DOAC-treated patients requiring urgent anticoagulant reversal, limited evidence from in vitro studies, animal bleeding models, human volunteer studies (in vivo and in vitro) and case series suggest that coagulation factor replacement with prothrombin complex concentrate (PCC) and activated PCC (FEIBA) may contribute to hemostasis. However, the safety and efficacy of these agents and the optimal dosing strategies remain uncertain.

SUBMITTER: Shaw JR 

PROVIDER: S-EPMC6055488 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.

Shaw Joseph R JR   Siegal Deborah M DM  

Research and practice in thrombosis and haemostasis 20180326 2


The direct oral anticoagulants (DOACs) are used for stroke prevention in atrial fibrillation (SPAF) and the prevention and treatment of venous thromboembolic disease (VTE). Although DOAC-associated bleeding events are less frequent as compared to vitamin K antagonists, there is significant concern surrounding physicians' ability to evaluate and manage DOAC-associated bleeding when it does occur. Idarucizumab is a specific reversal agent for dabigatran and is the agent of choice for dabigatran re  ...[more]

Similar Datasets

| S-EPMC5529093 | biostudies-other
| S-EPMC5296289 | biostudies-literature
| S-EPMC6142515 | biostudies-literature
| S-EPMC5499974 | biostudies-literature
| S-EPMC6963825 | biostudies-literature
| S-EPMC7826504 | biostudies-literature
| S-EPMC4167197 | biostudies-literature
| S-EPMC6423941 | biostudies-literature
| S-EPMC5852445 | biostudies-other
| S-EPMC6206466 | biostudies-other